Navigation Links
Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
Date:10/10/2008

alyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System. Results from more than 22,000 patients will focus on safety and efficacy, and will highlight outcomes within high-risk lesion subgroups and patients with serious co-morbid conditions. The Company plans to issue a press release at this time.

-- HORIZONS AMI data. At 11:00 a.m., Gregg W. Stone, M.D., will present data from the featured trial of the day "HORIZONS AMI: A Prospective Randomized Trial of Paclitaxel-Eluting Stents vs. Bare-Metal Stents in Patients with Acute ST-Segment Elevation Myocardial Infarction" in the Main Arena. The HORIZONS AMI trial is a randomized, controlled clinical trial designed to compare TAXUS stents to bare-metal stents in 3,400 AMI (acute myocardial infarction) patients. The Company plans to issue a press release at this time.

-- SYNTAX Sessions. From 10:15 a.m. -- 12:30 p.m., an additional series of sessions moderated by Dean J. Kereiakes, M.D., and Craig R. Smith, M.D., titled "Coronary Artery Disease I: Revascularization Controversies" will occur in Room 206. Details on the topics and presenters can be found in the official TCT program.

Boston Scientific will present its latest innovations at booth 814 on Level 2 of the Exhibition Hall, including the TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System, which recently became the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter.

The safety and effectiveness of the TAXUS Express Stent has not been established in patients with left main, three vessel disease, or an acute MI. In the U.S., the TAXUS Liberte Stent is an investigational device and is not available for sale.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visi
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CardioVascular Institute enrolled the first patient in Pennsylvania ... in a trial assessing the safety and effectiveness ... main artery of the leg. The new stent allows for ... stent fracture or re-narrowing after the stent is placed. ... the BioMimics 3D Stent System and will enroll 280 subjects ...
(Date:8/27/2015)...  Lightwave Logic, Inc. (OTCQB: LWLG), a technology ... Generation Photonic Devices and Non-Linear Optical Polymer Materials ... data communications and optical computing, announced today that ... to the Company,s Board of Directors. ... is widely recognized with wide-ranging experience across many ...
(Date:8/27/2015)... SAN FRANCISCO, Calif. , Aug. 27, 2015 ... Probody™ therapeutics for the treatment of cancer, today ... a member of the company,s Board of Directors, ... formerly led immuno-oncology at Eli Lilly and AstraZeneca, ... the first FDA approved checkpoint inhibitor, at Bristol-Myers ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... May 7, 2012  AssureRx Health, Inc. today announced ... the growing number of children and adults diagnosed ... pharmacogenomic test can assist clinicians with important medication ... individual patients tolerate ADHD medications. ...
...  BioElectronics Corporation (OTC-PINK: BIEL), the maker of disposable, ... announced the completion of a randomized, controlled trial ... product.  ActiPatch uses pulsed electromagnetic field therapy to ... injured tissue. A double blind, ...
Cached Medicine Technology:AssureRx Health Launches Personalized Medicine Test for ADHD 2AssureRx Health Launches Personalized Medicine Test for ADHD 3BioElectronics' ActiPatch Reduces Muscle Soreness in Runners 2
(Date:8/27/2015)... ... August 27, 2015 , ... StayWell, a ... Patient Education content is ICD-10 ready and available to all clients. All Krames ... code sets, which are more targeted and return a more comprehensive data set ...
(Date:8/27/2015)... ... 27, 2015 , ... Banc Intranets recently entered into a strategic ... both Johnson City, Tenn.-based firms to work synergistically to promote similar products to the ... caters to organizations in the financial, commercial and services sectors. The software, which is ...
(Date:8/27/2015)... ... 2015 , ... Susan Harris and the team at LifeStream Health ... pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch is ... the vaginal tissue, revitalizing cells so they make more collagen, an essential component in ...
(Date:8/27/2015)... ... 2015 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and Innovation, ... Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , Ms. ...
(Date:8/27/2015)... ... 2015 , ... Standifer Insurance Group, a full service insurance ... joint charity drive with the Meadow View Elementary School in Alabaster. , A ... many lack the simple supplies necessary for a productive scholastic career. In partnering ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 2Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 3Health News:Banc Intranets Forms Strategic Marketing Partnership with All Clear System 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 2Health News:Standifer Insurance Group Initiates Charity Drive to Provide School Supplies for Underprivileged Meadow View Elementary Students 3
... people seeking active participation in their communities has led researchers to ... engagement can now be considered a distinct retirement role, according to ... (Volume 48, Number 3). , The authors ... at least one day per week that directly impact the ...
... hours for participants in phase II trial , , ... drug called pegloticase lowered levels of uric acid in ... in most patients. , That,s the conclusion of a ... Savient Pharmaceuticals, the company that,s developing the drug. ...
... Trim Holdings,Inc. (Amex: ZTM ) announced today ... private placement subscription agreements pursuant to which we,sold ... for an,aggregate offering price of $2,370,000. Each of ... consists of a $100,000 24-month,senior secured promissory note ...
... overwhelmingly positive, PORTLAND, Ore., Sept. 3 ... doctor to others, according to a,popular online survey ... A,"Member Feedback" feature on the site allows Regence ... providers, including,physicians, dentists, other health care professionals and ...
... Amsterdam, September 3, 2008 A recent study (doi:10.1016/j.clim.2008.06.009) ... of the Clinical Immunology Society (CIS), describes a new ... human cells. The report demonstrates the characterization of specific ... providing information about the role these cells might play ...
... new survey by Medical Economics details surprising statistics on earnings and ... in wages for many doctors accompanied by a decrease in patient ... ... 2008 -- A newly-released 2008 Medical Economics survey focusing on earnings ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: